Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of “Buy” from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $11.60.

A number of equities research analysts have recently weighed in on AMRX shares. Wall Street Zen lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 13th. Barclays lifted their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. The Goldman Sachs Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its position in shares of Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company’s stock valued at $26,000 after purchasing an additional 3,107 shares during the period. Headlands Technologies LLC purchased a new stake in Amneal Pharmaceuticals in the 1st quarter worth $31,000. Amalgamated Bank raised its holdings in Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after acquiring an additional 1,367 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $52,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth about $81,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $7.96 on Friday. Amneal Pharmaceuticals has a one year low of $6.29 and a one year high of $9.48. The business’s 50 day simple moving average is $7.39 and its two-hundred day simple moving average is $7.94. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.71 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million during the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Sell-side analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.